Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes

被引:70
作者
Hand, WL
Hand, DL
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Res Dev, El Paso, TX 79905 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, El Paso, TX 79905 USA
关键词
azithromycin; antibiotic interactions with human PMN; intracelluar uptake of antibiotic;
D O I
10.1016/S0924-8579(01)00430-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Azithromycin achieves prolonged, high tissue concentrations in spite of low serum levels and obviously must be active at tissue sites of infection to be effective. These unique features prompted us to evaluate the interactions of azithromycin and human polymorphonuclear leukocytes (PMN). Uptake of radiolabeled antibiotic by PMN was determined by a velocity-gradient centrifugation technique and expressed as the ratio of cellular to extracellular drug concentration (CIE). Azithromycin was massively accumulated by human PMN (C/E = 387.2 at 2 h). Uptake was not influenced by inhibitors of cellular metabolism, but phagocytosis slightly inhibited the entry of azithromycin into PMN. After removal of extracellular drug, the release (efflux) of azithromycin from PMN was extremely slow. Agents which neutralize lysosomal pH, preventing protonation and trapping of azithromycin, markedly increased antibiotic efflux. Active concentration and prolonged retention of azithromycin by phagocytic cells should allow delivery and subsequent release of accumulated drug at sites of infection. (C) 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 42 条
[1]   Pharmacological considerations in the emergence of resistance [J].
Amsden, GW .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 11 :S7-S14
[2]   Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection -: The azithromycin in coronary artery disease:: Elimination of myocardial infection with Chlamydia (ACADEMIC) study [J].
Anderson, JL ;
Muhlestein, JB ;
Carlquist, J ;
Allen, A ;
Trehan, S ;
Nielson, C ;
Hall, S ;
Brady, J ;
Egger, M ;
Horne, B ;
Lim, T .
CIRCULATION, 1999, 99 (12) :1540-1547
[3]  
BALDWIN DR, 1990, EUR RESPIR J, V3, P886
[4]   INVITRO AND INVIVO INTRALEUKOCYTIC ACCUMULATION OF AZITHROMYCIN (CP-62, 993) AND ITS INFLUENCE ON EXVIVO LEUKOCYTE CHEMILUMINESCENCE [J].
BONNET, M ;
VANDERAUWERA, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1302-1309
[5]  
Boyum A., 1976, SCAND J IMMUNOL S, P9
[6]   KINETICS OF ERYTHROMYCIN UPTAKE AND RELEASE BY HUMAN-LYMPHOCYTES AND POLYMORPHONUCLEAR LEUKOCYTES [J].
DETTE, GA ;
KNOTHE, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (01) :73-82
[7]   AZITHROMYCIN INHIBITION OF INTRACELLULAR LEGIONELLA-MICDADEI [J].
DONOWITZ, GR ;
EARNHARDT, KI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2261-2264
[9]   Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes [J].
Fietta, A ;
Merlini, C ;
Grassi, GG .
JOURNAL OF CHEMOTHERAPY, 1997, 9 (01) :23-31
[10]   THE PHARMACOKINETICS OF AZITHROMYCIN IN HUMAN SERUM AND TISSUES [J].
FOULDS, G ;
SHEPARD, RM ;
JOHNSON, RB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :73-82